Parsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Parsatuzumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Parsatuzumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Parsatuzumab. |
| Estrone | Estrone may increase the thrombogenic activities of Parsatuzumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Parsatuzumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Parsatuzumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Parsatuzumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Parsatuzumab. |
| Estriol | Estriol may increase the thrombogenic activities of Parsatuzumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Parsatuzumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Parsatuzumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Parsatuzumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Parsatuzumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Parsatuzumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Parsatuzumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Parsatuzumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Parsatuzumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Parsatuzumab. |
| Equol | Equol may increase the thrombogenic activities of Parsatuzumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Parsatuzumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Parsatuzumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Parsatuzumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Parsatuzumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Parsatuzumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Parsatuzumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Parsatuzumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Parsatuzumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Parsatuzumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Parsatuzumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Parsatuzumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Parsatuzumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Parsatuzumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Parsatuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Parsatuzumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Parsatuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Parsatuzumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Parsatuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Parsatuzumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Parsatuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Parsatuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Parsatuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Parsatuzumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Parsatuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Parsatuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Parsatuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Parsatuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Parsatuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Parsatuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Parsatuzumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Parsatuzumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Parsatuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Parsatuzumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Parsatuzumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Parsatuzumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Parsatuzumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Parsatuzumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Parsatuzumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Parsatuzumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Parsatuzumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Parsatuzumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Parsatuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Parsatuzumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Parsatuzumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Parsatuzumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Parsatuzumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Parsatuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Parsatuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Parsatuzumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Parsatuzumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Parsatuzumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Parsatuzumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Parsatuzumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Parsatuzumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Parsatuzumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Parsatuzumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Parsatuzumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Parsatuzumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Parsatuzumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Parsatuzumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Parsatuzumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Parsatuzumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Parsatuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Parsatuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Parsatuzumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Parsatuzumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Parsatuzumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Parsatuzumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Parsatuzumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Parsatuzumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Parsatuzumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Parsatuzumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Parsatuzumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Parsatuzumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Parsatuzumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Parsatuzumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Parsatuzumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Parsatuzumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Parsatuzumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Parsatuzumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Parsatuzumab. |